GLASGOW, Scotland, November 4, 2013 /PRNewswire/ --
MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that CEO Dr Miroslav Ravic will present at Bio-Europe 2013 in Vienna, Austria (4-6 November). Details of the presentation on 6 November are listed below.
Dr Ravic will highlight MGB Biopharma's recent rapid progress in developing a truly novel class of anti-infectives. The Company's lead candidate MGB-BP-3 is an antibacterial active against a broad range of multi-resistant Gram-positive pathogens. The Company has completed preclinical development of an oral formulation that is ready to enter the clinic for Clostridium difficile. In addition, MGB Biopharma is developing an intravenous formulation of MGB-BP-3 for hospital acquired Gram-positive infections and this is expected to be IND-ready by the end of 2014.
MGB-based anti-infectives have the potential to deliver significant advantages over current approaches including broad, bactericidal activity against multi-resistant Gram-positive and Gram-negative pathogens. The platform also promises to deliver compounds that are active against certain viruses, fungi and parasites. MGB's anti-infectives are based on its minor groove binder (MGB) technology platform.
Dr Miroslav Ravic, CEO of MGB Biopharma, said: "Antimicrobial resistance is clearly a major global public health concern. Yet, the lack of truly novel agents, even among late stage candidates, means that, as an industry, we are ill equipped to tackle this problem. We believe that MGB's truly novel minor groove binder technology platform, could for the first time in a more than a decade, provide novel agents that offer a real breakthrough in addressing antimicrobial resistance. In particular our lead candidate MGB-BP-3 has shown significant antibacterial activity against a range of Gram positive pathogens and we expect to announce further progress with our on-going programs with MGB-BP-3 in the coming months."
Details of the presentation are as follow:
Title: Infectious Diseases Presentation stream: MGB Biopharma Limited
Location: Level 1, Schubert 4
Venue: Messe Wien Exhibition and Congress Center
About MGB Biopharma
MGB Biopharma is developing a truly novel class of anti-infectives. MGB's lead candidate, MGB-BP-3, is a broad spectrum antibacterial which is active against key multi-resistant Gram positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for Clostridium difficile that is ready to enter the clinic, while an IV formulation for a range of Gram positive infections is in late-stage preclinical development.
MGB's anti-infective drug development capabilities are driven by its broad anti-infective platform, which has the potential to generate truly novel compounds active against other infectious diseases such as Gram negative pathogens as well parasites and fungi.
MGB's anti-infectives are based on minor groove binders (MGBs). Minor groove binders have a new mode of action that offers significant advantages over existing anti-infectives, such as being more bactericidal and active against a broad range of drug-resistant bacteria.
MGB has close links with the University of Strathclyde, with exclusive worldwide licence rights to Strathclyde's MGB patents for all fields expect anticancer. The Company intends to work with partners to fully capitalize on the multiple value creating opportunities offered by its broad and novel anti-infectives platform.
The Company was founded in 2010 and is headquartered in Glasgow, Scotland. It is backed by Scotland's investors including Archangel Informal Investment, Barwell, TriCapital and Scottish Co-Investment Fund. For more information please visit http://www.mgb-biopharma.com.
For further information, please contact:
Gavin Clark, Chief Business Officer
Citigate Dewe Rogerson
David Dible/Sita Shah
SOURCE MGB Biopharma